Literature DB >> 12669383

S-1360 Shionogi-GlaxoSmithKline.

Andreas Billich1.   

Abstract

Shionogi and GlaxoSmithKline, as the joint venture company Shionogi-GlaxoSmithKline Pharmaceuticals, is developing S-1360, an HIV integrase inhibitor as a potential treatment for HIV infection. As of October 2002, phase II trials were ongoing and launch is expected in 2004/2005.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12669383

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  25 in total

1.  In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.

Authors:  Masanori Kobayashi; Tomokazu Yoshinaga; Takahiro Seki; Chiaki Wakasa-Morimoto; Kevin W Brown; Robert Ferris; Scott A Foster; Richard J Hazen; Shigeru Miki; Akemi Suyama-Kagitani; Shinobu Kawauchi-Miki; Teruhiko Taishi; Takashi Kawasuji; Brian A Johns; Mark R Underwood; Edward P Garvey; Akihiko Sato; Tamio Fujiwara
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

2.  Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects.

Authors:  S P Korolev; Yu Yu Agapkina; M B Gottikh
Journal:  Acta Naturae       Date:  2011-07       Impact factor: 1.845

Review 3.  Authentic HIV-1 integrase inhibitors.

Authors:  Chenzhong Liao; Christophe Marchand; Terrence R Burke; Yves Pommier; Marc C Nicklaus
Journal:  Future Med Chem       Date:  2010-07       Impact factor: 3.808

4.  HIV integrase inhibitors with nucleobase scaffolds: discovery of a highly potent anti-HIV agent.

Authors:  Vasu Nair; Guochen Chi; Roger Ptak; Nouri Neamati
Journal:  J Med Chem       Date:  2006-01-26       Impact factor: 7.446

5.  Synthesis, biological evaluation and 3D-QSAR studies of 3-keto salicylic acid chalcones and related amides as novel HIV-1 integrase inhibitors.

Authors:  Horrick Sharma; Shivaputra Patil; Tino W Sanchez; Nouri Neamati; Raymond F Schinazi; John K Buolamwini
Journal:  Bioorg Med Chem       Date:  2011-03-01       Impact factor: 3.641

6.  Dihydroxythiophenes are novel potent inhibitors of human immunodeficiency virus integrase with a diketo acid-like pharmacophore.

Authors:  S Kehlenbeck; U Betz; A Birkmann; B Fast; A H Göller; K Henninger; T Lowinger; D Marrero; A Paessens; D Paulsen; V Pevzner; R Schohe-Loop; H Tsujishita; R Welker; J Kreuter; H Rübsamen-Waigmann; F Dittmer
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

7.  A quantum mechanic/molecular mechanic study of the wild-type and N155S mutant HIV-1 integrase complexed with diketo acid.

Authors:  Cláudio Nahum Alves; Sergio Martí; Raquel Castillo; Juan Andrés; Vicent Moliner; Iñaki Tuñón; Estanislao Silla
Journal:  Biophys J       Date:  2007-11-02       Impact factor: 4.033

8.  Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations.

Authors:  Valery Fikkert; Bénédicte Van Maele; Jo Vercammen; Anke Hantson; Barbara Van Remoortel; Martine Michiels; Cristina Gurnari; Christophe Pannecouque; Marc De Maeyer; Yves Engelborghs; Erik De Clercq; Zeger Debyser; Myriam Witvrouw
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.

Authors:  Edward P Garvey; Brian A Johns; Margaret J Gartland; Scott A Foster; Wayne H Miller; Robert G Ferris; Richard J Hazen; Mark R Underwood; Eric E Boros; James B Thompson; Jason G Weatherhead; Cecilia S Koble; Scott H Allen; Lee T Schaller; Ronald G Sherrill; Tomokazu Yoshinaga; Masanori Kobayashi; Chiaki Wakasa-Morimoto; Shigeru Miki; Koichiro Nakahara; Takeshi Noshi; Akihiko Sato; Tamio Fujiwara
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

Review 10.  Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors.

Authors:  Erik Serrao; Srinivas Odde; Kavya Ramkumar; Nouri Neamati
Journal:  Retrovirology       Date:  2009-03-05       Impact factor: 4.602
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.